A European consensus conference on endometrial carcinoma was held in 2014 to produce
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …

The first joint European Society for Medical Oncology (ESMO), European SocieTy for
Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) …

Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE)
exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) …

Background PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR)
endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal …

B-cells play a key role in cancer suppression, particularly when aggregated in tertiary lymphoid
structures (TLS). Here, we investigate the role of B-cells and TLS in endometrial cancer (…

Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental
in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are …

PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …

Purpose: Recommendations for adjuvant treatment for women with early-stage endometrial
carcinoma are based on clinicopathologic features. Comprehensive genomic …

Mesenchymal stromal cells (MSCs) are currently under investigation for the treatment of
inflammatory disorders, including Crohn's disease. MSCs are pluripotent cells with …

This study aimed to investigate whether molecular analysis can be used to refine risk
assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial …